AstraZeneca PLC (AZN)vsCEL-SCI Corp (CVM)
AZN
AstraZeneca PLC
$166.27
-1.05%
HEALTHCARE · Cap: $263.12B
CVM
CEL-SCI Corp
$1.62
+0.62%
HEALTHCARE · Cap: $27.97M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 214866854% more annual revenue ($61.37B vs $28,560). AZN leads profitability with a 17.0% profit margin vs 0.0%. CVM appears more attractively valued with a PEG of 1.12. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
CVM
Avoid27
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.3%
Fair Value
$196.36
Current Price
$166.27
$30.09 discount
Intrinsic value data unavailable for CVM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Reasonable price relative to book value
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.44 suggests the stock is reasonably priced for its growth.
Bull Case : CVM
The strongest argument for CVM centers on Price/Book. PEG of 1.12 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : CVM
The primary concerns for CVM are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while CVM is a value play — different risk/reward profiles.
CVM carries more volatility with a beta of 0.56 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 27/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
CEL-SCI Corp
HEALTHCARE · BIOTECHNOLOGY · USA
CEL-SCI Corporation is dedicated to the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?